Covalon Technologies Ltd Stock Price, News & Analysis

Covalon Technologies (TSXV: COV; OTCQX: CVALF), a medical technologies company, has achieved DTC eligibility for its shares in the United States, enabling electronic clearing and settlement on the OTCQX Market. This development streamlines trading processes and reduces transaction costs for U.S. investors.

The company also confirmed the previously announced appointment of Kim Crooks to its Board of Directors and the granting of 150,000 stock options at an exercise price of $2.50 per share. The options will vest over three years and expire in five years, subject to TSX Venture Exchange requirements and shareholder approval at the 2026 Annual General Meeting.

Covalon Technologies (OTCQX:CVALF), an advanced medical technologies company, has scheduled its Q3 Fiscal 2025 financial results announcement for Wednesday, August 21, 2025, before markets open.

The company will host a conference call and webcast at 8:30am ET on the same day to discuss the results. Participants can join via webcast or dial in using various phone numbers, including North American Toll-Free: 1-800-549-8228. The event will include a Q&A session where management will address questions from participants.

Covalon Technologies (OTCQX:CVALF), an advanced medical technologies company, has announced it will release its Q3 Fiscal 2025 financial results on Thursday, August 21, 2025, before markets open. The company will host a conference call and webcast to discuss the results at 8:30am ET on the same day.

Investors can participate via webcast or dial in using various phone numbers including North American Toll-Free: 1-800-549-8228. The conference call will include a Q&A session where participants can interact with company management. A recording will be available on Covalon's website afterward.

Covalon Technologies (CVALF) reported its fiscal 2025 Q2 results, marking its fifth consecutive quarter of profitability. Year-to-date revenue grew 21% to $15.7M, while Adjusted EBITDA increased by 57%. Q2 revenue was $7.6M, with a gross margin of 55%. The company's U.S. Vascular Access and Surgical Consumables segment showed 19% sequential quarterly growth and is up 46% year-to-date. International sales reached a 5-year high of $2.3M in Q2, growing 44% year-to-date. The company maintains a strong financial position with $18M in cash and no debt. Covalon recently signed a major distribution agreement with Paul Hartmann USA and has retained financial advisors to explore M&A opportunities. The company's North American manufacturing strategy has provided a competitive advantage in the current tariff environment.

Covalon Technologies (CVALF) has announced that results from a clinical study of its VALGuard® Vascular Access Line Guard will be presented at two major scientific meetings and is advancing towards publication. The independent study focused on reducing Central Line-Associated Blood Stream Infections (CLABSIs) across critical and acute care units. CLABSIs affect hundreds of thousands of patients annually with a 15-20% mortality rate. The research will be presented at the Association for Vascular Access Annual Scientific Meeting in September and the American Nurses Credentialing Center Magnet Pathway Conference in October, which attracts over 11,000 nursing professionals. Major U.S. hospitals are incorporating VALGuard® into their infection prevention programs to protect intravenous lines from contamination.

Covalon Technologies (TSXV: COV; OTCQX: CVALF), a medical technologies company, has scheduled the release of its Q2 Fiscal 2025 financial results for Wednesday, May 28, 2025, before markets open. The company will host a conference call and webcast at 8:30am ET on the same day to discuss the results.

Investors can participate through the webcast or by dialing into the conference call using the following numbers: North American Toll-Free: 1-800-549-8228, Toronto Local: 289-819-1520, or New York Local: 646-564-2877 (Conference ID: 92114). A recording will be available on Covalon's website, and financial statements can be accessed through SEDAR PLUS.

Covalon Technologies (CVALF) has engaged Origin Merchant Partners as its financial and strategic advisor to explore opportunities for maximizing shareholder value. The company is considering various options including joint ventures, strategic partnerships, acquisitions, mergers, licensing deals, NASDAQ listing, stock buybacks using its $18 million net cash balance, and potential spinoffs of its business segments. The company's Advanced Wound Care segment has grown over 4x in the U.S. market in four years, contributing $10 million in Adjusted EBITDA. The Vascular Access and Surgical Consumables segment has achieved over 50% compound annual growth in the U.S. market over the past three fiscal years. Management believes Covalon is undervalued, trading at a mid-single-digit Adjusted EBITDA multiple compared to higher-multiple med-tech peers.

Covalon Technologies Ltd. (CVALF) has announced the promotion of Kim Crooks to Chief Operating Officer (COO) and her appointment to the company's Board of Directors, effective immediately. Crooks, who rejoined Covalon in early 2024 as Senior Vice President – Operations, previously served as Vice President of Operations from 2012 to 2022. In her role, she has been overseeing production, operations, Quality Assurance, Quality Control, Regulatory Affairs, and Human Resources.

As part of her appointment, Crooks will receive 150,000 stock options vesting equally over three years at market price. Both her Board appointment and stock option grant are subject to TSX Venture Exchange approval.

Covalon Technologies (TSXV: COV; OTCQX: CVALF) will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 6, 2025, at 2:30 pm ET. CEO Brent Ashton will lead the presentation in Room 104 B at the Metro Toronto Convention Centre.

The presentation will focus on Covalon's mission to prevent healthcare complications through patient-centered technologies. Ashton will discuss the company's strong financial position and growth drivers. The conference, running May 5-6, 2025, provides a platform for healthcare companies and investors to connect.

Investors can register for one-on-one meetings with Covalon's management. Those unable to attend can learn more about Covalon's solutions through their website and social media channels including LinkedIn, Facebook, Instagram, and X.